Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits: efficacy, safety and non-compartmental pharmacokinetics

被引:26
作者
Groll, AH
Gonzalez, CE
Giri, N
Kligys, K
Love, W
Peter, J
Feuerstein, E
Bacher, J
Piscitelli, SC
Walsh, TJ
机构
[1] NCI, Immunocompromised Host Sect, Pediat Oncol Branch, NIH, Bethesda, MD 20892 USA
[2] NIH, Warren Grant Magnuson Clin Ctr, Dept Radiol, Bethesda, MD 20892 USA
[3] NIH, Natl Ctr Res Resources, Surg Serv, Vet Resources Program, Bethesda, MD 20892 USA
[4] NIH, Pharmacokinet Res Lab, Dept Pharm, Warren Grant Magnuson Clin Ctr, Bethesda, MD 20892 USA
关键词
D O I
10.1093/jac/43.1.95
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The activity of liposomal nystatin against invasive pulmonary aspergillosis was investigated in persistently neutropenic rabbits. Treatment groups included liposomal nystatin at dosages of 1,2 and 4 mg/kg/day intravenously, or amphotericin B deoxycholate 1 mg/kg/day administered intravenously after normal saline loading. As compared with untreated controls, liposomal nystatin administered at 2 and 4 mg/kg/day prolonged survival and reduced fungus-mediated tissue injury and excess lung weight at post-mortem in a similar manner to amphotericin B. Although amphotericin B was superior in clearing infected lung tissue, treatment with all regimens of liposomal nystatin led to a significant reduction in pulmonary fungal tissue burden. During treatment, ultrafast CT-scan demonstrated ongoing resolution of pulmonary lesions at 2 and 4 mg/kg/day, but not at 1 mg/kg/day. With the exception of mild increases in blood urea nitrogen (BUN) and serum creatinine values during treatment at 2 and 4 mg/kg/day, which were similar to those found in amphotericin B-treated rabbits, liposomal nystatin was well tolerated. Preliminary pharmacokinetic studies in non-infected animals established linear drug disposition of liposomal nystatin in plasma over the investigated dosage range and peak plasma levels above the MIC for the test strain after multiple daily dosing for 7 days. Liposomal nystatin increased survival and provided reduced tissue injury, effective microbiological clearance and tolerable side effects in experimental pulmonary aspergillosis in persistently neutropenic rabbits, thus providing a rational basis for further investigations in clinical trials.
引用
收藏
页码:95 / 103
页数:9
相关论文
共 31 条
[21]   FORMULATION, TOXICITY, AND ANTIFUNGAL ACTIVITY INVITRO OF LIPOSOME-ENCAPSULATED NYSTATIN AS THERAPEUTIC AGENT FOR SYSTEMIC CANDIDIASIS [J].
MEHTA, RT ;
HOPFER, RL ;
GUNNER, LA ;
JULIANO, RL ;
LOPEZBERESTEIN, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (12) :1897-1900
[22]   NOSOCOMIAL PNEUMONIA IN ADULT PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION - A 9-YEAR STUDY [J].
PANNUTI, CS ;
GINGRICH, RD ;
PFALLER, MA ;
WENZEL, RP .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (01) :77-84
[23]   PHARMACOKINETICS OF LIPOSOMAL NYSTATIN IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
RIOS, A ;
ROSENBLUM, M ;
CROFOOT, G ;
LENK, RP ;
HAYMAN, A ;
LOPEZBERESTEIN, G .
JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (01) :253-254
[24]   10TH ANNIVERSARY ISSUE - EDITORIAL [J].
SCHNEIDER, HJ .
INFORMATION SYSTEMS, 1985, 10 (01) :1-1
[25]  
SHAH VP, 1991, EUR J DRUG METAB PH, V16, P249
[26]  
VAUGHAN VC, 1992, TXB PEDIAT, P40
[27]   Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice [J].
Wallace, TL ;
Paetznick, V ;
Cossum, PA ;
LopezBerestein, G ;
Rex, JH ;
Anaissie, E .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2238-2243
[28]   TISSUE HOMOGENIZATION WITH STERILE REINFORCED POLYETHYLENE BAGS FOR QUANTITATIVE CULTURE OF CANDIDA-ALBICANS [J].
WALSH, TJ ;
MCENTEE, C ;
DIXON, DM .
JOURNAL OF CLINICAL MICROBIOLOGY, 1987, 25 (05) :931-932
[29]   THERAPEUTIC MONITORING OF EXPERIMENTAL INVASIVE PULMONARY ASPERGILLOSIS BY ULTRAFAST COMPUTERIZED-TOMOGRAPHY, A NOVEL, NONINVASIVE METHOD FOR MEASURING RESPONSES TO ANTIFUNGAL THERAPY [J].
WALSH, TJ ;
GARRETT, K ;
FEUERSTEIN, E ;
GIRTON, M ;
ALLENDE, M ;
BACHER, J ;
FRANCESCONI, A ;
SCHAUFELE, R ;
PIZZO, PA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (05) :1065-1069
[30]  
WALSH TJ, 1988, LAB ANIM SCI, V38, P467